ヘモグロビン異常症の世界市場：2024-2031年

ヘモグロビン異常症市場は予測期間（2024-2031年）にCAGR 7.9％で成長すると予測されます。ヘモグロビン異常症は、ヘモグロビン分子のDNA遺伝子の変異によって引き起こされます。ヘモグロビン分子の構造異常は欠陥のある赤血球を生成し、これが鎌状赤血球症の根本原因です。さらに、ヘモグロビンに関連した疾患はアジアやアフリカ地域で多く見られます。世界保健機関（WHO）によれば、世界人口の7.0％がヘモグロビン異常症に罹患しています。WHOはまた、30,000-40,000人の新生児が遺伝的疾患として両親から重度のヘモグロビン異常症を受け継いでいると推定しています。

市場力学

ヘモグロビン異常症に対する意識の高まり

ヘモグロビン異常症に関する意識の高まりと、早期診断に向けた政府の取り組みが市場成長の原動力となっています。さらに、医療インフラが不十分で、病気の診断や治療のレベルが低いことも、市場成長の原動力になると予想されます。また、政府の取り組みによる献血数の増加が市場成長を後押ししています。さらに、鎌状赤血球症やサラセミア患者の多さも、予測期間中の市場成長を後押ししています。

ヘモグロビン異常症の有病率の上昇が市場成長を促進

世界的には、鎌状赤血球貧血、サラセミア、Hb C、Hb Eなどのヘモグロビン異常症の有病率の上昇が市場促進要因であると推定されます。WHOによると、ヘモグロビン異常症は229カ国の60.0％以上で流行しており、出生数の70.0％以上に影響を及ぼしています。米国疾病予防管理センター（CDC）が2015年に発表した報告書によると、鎌状赤血球症（SCD）とα（a）およびβ（B）サラセミアなどの他のヘモグロビン異常症を特定するための新生児の初期スクリーニングも、米国の人口動態の変化により近年大きな注目を集めています。

市場セグメンテーション

世界のヘモグロビン異常症市場を詳細に分析した結果、以下のように区分：

• タイプ別では、市場はサラセミア、鎌状赤血球症、その他に区分されます。
• 治療に基づき、市場はモノクローナル抗体薬、ACE阻害薬、ヒドロキシ尿素、その他に区分されます。
• 販売チャネルに基づくと、市場は病院薬局、オンラインプロバイダー、ドラッグストア・小売薬局に区分されます。

鎌状赤血球症が最大セグメントとなる見込み

鎌状赤血球症セグメントは、市場で最大のシェアを占めると予想されます。鎌状赤血球症診断市場は近年、顕著な動向を目の当たりにしています。一つの大きな動向は、革新的な診断技術の開発と採用です。次世代シーケンシングや分子診断法を含む遺伝子検査の進歩により、鎌状赤血球症とその変異型のより正確で効率的な同定が可能になった。また、ポイントオブケア検査（POCT）機器や迅速診断キットも登場し、さまざまな医療環境で迅速かつ簡便なスクリーニングが可能となっています。例えば、2023年5月、Molbio Diagnostics社はShanMukha Innovations社と共同で、ヘモグロビン異常症関連疾患を診断するための合理的な価格のPOCT診断装置を設計、開発、商品化しました。

モノクローナル抗体薬セグメントが大きな市場シェアを占める

モノクローナル抗体薬セグメントは、ヘモグロビン異常症市場でかなりの市場シェアを占めています。その理由は、治療に十分な薬剤が利用できることと、サラセミア患者がモノクローナル抗体薬によって健康的な回復を示すからです。モノクローナル抗体は、人体が免疫系の活動を模倣して作る抗体のようなものです。モノクローナル抗体は、血液から特定の抗体を取り出してクローン化する過程で作られます。

地域別展望

世界のヘモグロビン異常症市場は、北米（米国、カナダ）、欧州（英国、イタリア、スペイン、ドイツ、フランス、その他欧州地域）、アジア太平洋（インド、中国、日本、韓国、その他アジア太平洋地域）、世界のその他の地域（中東とアフリカ、ラテンアメリカ）を含む地域別にさらに細分化されています。

急速な市場成長を遂げるアジア太平洋地域

予測期間中、アジア太平洋地域が最も速い成長率を示すと予想されます。鎌状赤血球症およびサラセミア患者の多さが、今後数年間の市場成長を促進すると予想されます。ヘモグロビン異常症を患う患者に提供される標準治療を改善するための政府の好意的な取り組みが、この地域の市場成長に寄与しています。例えば、2023年5月、連邦保健家族福祉担当大臣は、保健省のサラセミアBal Sewa Yojanaの第3期を開始しました。政府はまた、Thalassemia Bal Sewa Yojanaポータルを立ち上げました。

北米が主要市場シェアを占める

北米は、人々のヘモグロビン異常症に対する意識の高まりと医療施設の改善により、大きなシェアを占めています。様々な団体が様々なプログラムを実施することで認知度を広めています。例えば、SCDAAは米国の全国組織であり、鎌状赤血球症の患者やその家族に対する啓発、アドボカシー、支援を推進しています。SCDAAは、鎌状赤血球症の理解を深め、鎌状赤血球症患者の生活を改善するために、資料や教材を提供し、イベントを開催しています。ヘモグロビン異常症を治療するための新規治療法を開発するための研究を促進するために、研究組織や政府機関が行っている様々な取り組みが、この地域の市場成長に貢献していると思われます。

目次

第1章 レポート概要

• 業界の現状分析と成長ポテンシャルの展望
• 調査方法とツール
• 市場内訳
  • セグメント別
  • 地域別

第2章 市場概要と洞察

• 調査範囲
• アナリストの洞察と現在の市場動向
  • 主要市場動向
  • 推奨事項
  • 結論

第3章 競合情勢

• 主要企業分析
• Novartis AG
  • 概要
  • 財務分析
  • SWOT分析
  • 最近の動向
• Pfizer Inc.
  • 会社概要
  • 財務分析
  • SWOT分析
  • 最近の動向
• Sangamo Therapeutics
  • 概要
  • 財務分析
  • SWOT分析
  • 最近の動向
• Sanofi SA
  • 概要
  • 財務分析
  • SWOT分析
  • 最近の動向
• 主要戦略分析

第4章 市場セグメンテーション

• ヘモグロビン異常症の世界市場：タイプ別
  • サラセミア
  • 鎌状赤血球症
  • その他（ヘモグロビン（Hb）変異体）
• ヘモグロビン異常症の世界市場：治療別
  • モノクローナル抗体薬
  • ACE阻害剤
  • ヒドロキシ尿素
  • その他（輸血、鉄キレート療法、骨髄移植）
• ヘモグロビン異常症の世界市場：流通チャネル別
  • 病院薬局
  • オンラインプロバイダー
  • ドラッグストア・小売薬局

第5章 地域別分析

• 北米
  • 米国
  • カナダ
• 欧州
  • 英国
  • ドイツ
  • イタリア
  • スペイン
  • フランス
  • その他欧州
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• 世界のその他の地域
  • ラテンアメリカ
  • 中東・アフリカ

第6章 企業プロファイル

• Abbott Laboratories
• Alnylam Pharmaceuticals, Inc.
• BIOGEN Inc.
• Bio-Rad Laboratories Inc.
• Bioverativ Inc.
• Bluebird Bio Inc.
• Canthera Discovery Ltd.
• Celgene Corporation
• Danaher Corporation
• Emmaus Medical, Inc.
• Gamida Cell Ltd.
• Global Blood Therapeutics, Inc.
• Merck & Co. Inc.
• Mindray Medical International Ltd.
• Nihon Kohden Corporation
• PerkinElmer, Inc.
• Prolong Pharmaceuticals LLC
• Silence Therapeutics

LIST OF TABLES

• 1. Global Hemoglobinopathies Market Research And Analysis By Type, 2023-2031 ($ Million)
• 2. Global Thalassemia Hemoglobinopathies Market Research And Analysis By Region, 2023-2031 ($ Million)
• 3. Global Sickle Cell Disease Hemoglobinopathies Market Research And Analysis By Region, 2023-2031 ($ Million)
• 4. Global Others Hemoglobinopathies Market Research And Analysis By Region, 2023-2031 ($ Million)
• 5. Global Hemoglobinopathies Market Research And Analysis By Therapy, 2023-2031 ($ Million)
• 6. Global Monoclonal Antibody Medication For Hemoglobinopathies Market Research And Analysis By Region, 2023-2031 ($ Million)
• 7. Global Ace Inhibitors For Hemoglobinopathies Market Research And Analysis By Region, 2023-2031 ($ Million)
• 8. Global Hydroxyurea For Hemoglobinopathies Market Research And Analysis By Region, 2023-2031 ($ Million)
• 9. Global Others Hemoglobinopathies Therapy Market Research And Analysis By Region, 2023-2031 ($ Million)
• 10. Global Hemoglobinopathies Market Research And Analysis By Distribution Channel, 2023-2031 ($ Million)
• 11. Global Hemoglobinopathies Via Hospital Pharmacy Market Research And Analysis By Region, 2023-2031 ($ Million)
• 12. Global Hemoglobinopathies Via Online Providers Market Research And Analysis By Region, 2023-2031 ($ Million)
• 13. Global Hemoglobinopathies Via Drug Stores And Retail Pharmacy Market Research And Analysis By Region, 2023-2031 ($ Million)
• 14. Global Hemoglobinopathies Market Research And Analysis By Region, 2023-2031 ($ Million)
• 15. North American Hemoglobinopathies Market Research And Analysis By Country, 2023-2031 ($ Million)
• 16. North American Hemoglobinopathies Market Research And Analysis By Type, 2023-2031 ($ Million)
• 17. North American Hemoglobinopathies Market Research And Analysis By Therapy, 2023-2031 ($ Million)
• 18. North American Hemoglobinopathies Market Research And Analysis By Distribution Channel, 2023-2031 ($ Million)
• 19. European Hemoglobinopathies Market Research And Analysis By Country, 2023-2031 ($ Million)
• 20. European Hemoglobinopathies Market Research And Analysis By Type, 2023-2031 ($ Million)
• 21. European Hemoglobinopathies Market Research And Analysis By Therapy, 2023-2031 ($ Million)
• 22. European Hemoglobinopathies Market Research And Analysis By Distribution Channel, 2023-2031 ($ Million)
• 23. Asia-Pacific Hemoglobinopathies Market Research And Analysis By Country, 2023-2031 ($ Million)
• 24. Asia-Pacific Hemoglobinopathies Market Research And Analysis By Type, 2023-2031 ($ Million)
• 25. Asia-Pacific Hemoglobinopathies Market Research And Analysis By Therapy, 2023-2031 ($ Million)
• 26. Asia-Pacific Hemoglobinopathies Market Research And Analysis By Distribution Channel, 2023-2031 ($ Million)
• 27. Rest Of The World Hemoglobinopathies Market Research And Analysis By Region, 2023-2031 ($ Million)
• 28. Rest Of The World Hemoglobinopathies Market Research And Analysis By Type, 2023-2031 ($ Million)
• 29. Rest Of The World Hemoglobinopathies Market Research And Analysis By Therapy, 2023-2031 ($ Million)
• 30. Rest Of The World Hemoglobinopathies Market Research And Analysis By Distribution Channel, 2023-2031 ($ Million)

LIST OF FIGURES

• 1. Global Hemoglobinopathies Market Share By Type, 2023 Vs 2031 (%)
• 2. Global Thalassemia Hemoglobinopathies Market Share By Region, 2023 Vs 2031 (%)
• 3. Global Sickle Cell Disease Hemoglobinopathies Market Share By Region, 2023 Vs 2031 (%)
• 4. Global Others Hemoglobinopathies Market Share By Region, 2023 Vs 2031 (%)
• 5. Global Hemoglobinopathies Market Share By Therapy, 2023 Vs 2031 (%)
• 6. Global Monoclonal Antibody Medication For Hemoglobinopathies Market Share By Region, 2023 Vs 2031 (%)
• 7. Global Ace Inhibitors For Hemoglobinopathies Market Share By Region, 2023 Vs 2031 (%)

Global Hydroxyurea For Hemoglobinopathies Market Share By Region, 2023 Vs 2031 (%)

• 8. Global Hemoglobinopathies Market Share By Distribution Channel, 2023 Vs 2031 (%)
• 9. Global Hemoglobinopathies Via Hospital Pharmacy Market Share By Region, 2023 Vs 2031 (%)
• 10. Global Hemoglobinopathies Via Online Providers Market Share By Region, 2023 Vs 2031 (%)
• 11. Global Hemoglobinopathies Via Drug Stores And Retail Pharmacy Market Share By Region, 2023 Vs 2031 (%)
• 12. Global Hemoglobinopathies Market Share By Region, 2023 Vs 2031 (%)
• 13. US Hemoglobinopathies Market Size, 2023-2031 ($ Million)
• 14. Canada Hemoglobinopathies Market Size, 2023-2031 ($ Million)
• 15. UK Hemoglobinopathies Market Size, 2023-2031 ($ Million)
• 16. France Hemoglobinopathies Market Size, 2023-2031 ($ Million)
• 17. Germany Hemoglobinopathies Market Size, 2023-2031 ($ Million)
• 18. Italy Hemoglobinopathies Market Size, 2023-2031 ($ Million)
• 19. Spain Hemoglobinopathies Market Size, 2023-2031 ($ Million)
• 20. Rest Of Europe Hemoglobinopathies Market Size, 2023-2031 ($ Million)
• 21. India Hemoglobinopathies Market Size, 2023-2031 ($ Million)
• 22. China Hemoglobinopathies Market Size, 2023-2031 ($ Million)
• 23. Japan Hemoglobinopathies Market Size, 2023-2031 ($ Million)
• 24. South Korea Hemoglobinopathies Market Size, 2023-2031 ($ Million)
• 25. Rest Of Asia-Pacific Hemoglobinopathies Market Size, 2023-2031 ($ Million)
• 26. Latin America Hemoglobinopathies Market Size, 2023-2031 ($ Million)
• 27. Middle East And Africa Hemoglobinopathies Market Size, 2023-2031 ($ Million)

Hemoglobinopathies Market Size, Share & Trends Analysis Report by Type (Thalassemia, Sickle Cell Disease, and Others), by Therapy (Monoclonal Antibody Medication, ACE inhibitors, Hydroxyurea, and Others), and by Distribution Channel (Hospital Pharmacy, Online Providers, and Drug Stores and Retail Pharmacy), Forecast Period (2024-2031)

Hemoglobinopathies market is anticipated to grow at a CAGR of 7.9% during the forecast period (2024-2031). Hemoglobinopathies are caused by a mutation in the gene of DNA of hemoglobin molecule. Structural abnormalities in the hemoglobin molecule generate defective red blood cells, which is a root cause of sickle cell disease. Furthermore, the presence of hemoglobin-related diseases is higher in Asia and Africa region. According to the World Health Organization (WHO), 7.0% of the world's population is affected by hemoglobinopathies. WHO also estimated that 30,000-40,000 newborn babies carry severe hemoglobinopathies from their parents as a genetic disorder.

Market Dynamics

Growing Awareness about Hemoglobinopathy

The increasing awareness regarding hemoglobinopathies and government initiatives to diagnose the diseases at an early stage are the driving factors of the market growth. Further, the insufficient healthcare infrastructure and low levels of disease diagnosis and treatments are expected to drive market growth. Also, the increasing number of blood donations in government initiatives is helping to boost market growth. Moreover, many patients with sickle cell disease & thalassemia are also helping to boost the market growth over the forecast period.

Rising Prevalence of Hemoglobin Disorders Drives the Market Growth

Globally, the rising prevalence of hemoglobin disorders such as sickle cell anemia, thalassemia, Hb C, and Hb E is estimated to be the high-impact rendering driver of the market. According to the WHO, hemoglobin disorders are endemic in over 60.0% of the 229 countries affecting over 70.0% of births. As per the report published by the Centers for Disease Control and Prevention (CDC) in 2015, the initial screening of newborns to identify sickle cell disease (SCD) along with other hemoglobin disorders such as alpha (a) and beta (B) thalassemia have also gained significant attention in recent years due to the change in the US demographics.

Market Segmentation

Our in-depth analysis of the global hemoglobinopathies market includes the following segments by type, therapy, and distribution channel:

• Based on type, the market is segmented into thalassemia, sickle cell disease, and others.
• Based on therapy, the market is segmented into monoclonal antibody medication, ace inhibitors, hydroxyurea, and others.
• Based on distribution channel, the market is segmented into hospital pharmacies, online providers, and drug stores and retail pharmacies.

Sickle Cell Disease is Projected to Emerge as the Largest Segment

The sickle cell disease segment is expected to hold the largest share of the market. The sickle cell disease diagnosis market has witnessed prominent trends in recent years. One substantial trend is the development and adoption of innovative diagnostic technologies. Advances in genetic testing, including next-generation sequencing and molecular diagnostics, have enabled more accurate and efficient identification of sickle cell disease and its variants. Point-of-care testing (POCT) devices and rapid diagnostic kits have also emerged, allowing for quick and convenient screening in various healthcare settings. For instance, in May 2023, Molbio Diagnostics collaborated with ShanMukha Innovations to design, develop, and commercialize reasonably priced point-of-care diagnostic devices for diagnosing hemoglobinopathy-related diseases.

Monoclonal Antibody Medication Segment to Hold a Considerable Market Share

The monoclonal antibody medication segment holds a considerable market share in the hemoglobinopathy market. It is because of the sufficient medications available for the therapy and because thalassemia patients show healthy recovery by monoclonal antibody medication. Monoclonal antibodies are like antibodies that a human body develops, which mimic the activity of the immune system. They are created through a process in which specific antibodies are drawn out of the blood and then cloned.

Regional Outlook

The global hemoglobinopathies market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).

Asia-Pacific to Experience the Rapid Market Growth

Asia-Pacific is anticipated to exhibit the fastest growth rate over the forecast period. The presence of many patients with sickle cell disease and thalassemia is expected to propel market growth in the coming years. Favorable government initiatives to improve the standard of care provided to patients affected with hemoglobinopathies contribute to the region's market growth. For instance, in May 2023, the Union Minister of State for Health and Family Welfare launched the third phase of the Thalassemia Bal Sewa Yojana of the Health Ministry. The government also launched the Thalassemia Bal Sewa Yojana Portal.

North America Holds Major Market Share

North America holds a significant share owing to increasing awareness of hemoglobinopathies among people and improving healthcare facilities. Various organizations spread awareness by conducting different programs. For instance, SCDAA is a national organization in the US that promotes awareness, advocacy, and support for individuals and families affected by sickle cell disease. They provide resources and educational materials and host events to increase understanding and improve the lives of those with the condition. Various initiatives undertaken by research organizations and government bodies to promote research to develop novel therapies for treating hemoglobinopathies are likely to contribute to the market growth in the region.

Market Players Outlook

The major companies serving the global hemoglobinopathies market include Novartis AG, Pfizer Inc., Sangamo Therapeutics, and Sanofi, among others. The market players are increasingly focusing on business expansion and product development by applying strategies such as collaborations, mergers, and acquisitions to stay competitive in the market. For instance, in March 2023, Bluebird Bio applied its sickle cell gene therapy, lovo-cel to the FDA for approval. The drug upon approval would compete with CRISPR Therapeutics and Vertex Pharmaceuticals. The therapy is expected to be commercialized by the second half of 2023.

Table of Contents

1. Report Summary

• Current Industry Analysis and Growth Potential Outlook
• 1.1. Research Methods and Tools
• 1.2. Market Breakdown
  • 1.2.1. By Segments
  • 1.2.2. By Region

2. Market Overview and Insights

• 2.1. Scope of the Report
• 2.2. Analyst Insight & Current Market Trends
  • 2.2.1. Key Market Trends
  • 2.2.2. Recommendations
  • 2.2.3. Conclusion

3. Competitive Landscape

• 3.1. Key Company Analysis
• 3.2. Novartis AG
  • 3.2.1. Overview
  • 3.2.2. Financial Analysis
  • 3.2.3. SWOT Analysis
  • 3.2.4. Recent Developments
• 3.3. Pfizer Inc.
  • 3.3.1. Overview
  • 3.3.2. Financial Analysis
  • 3.3.3. SWOT Analysis
  • 3.3.4. Recent Developments
• 3.4. Sangamo Therapeutics
  • 3.4.1. Overview
  • 3.4.2. Financial Analysis
  • 3.4.3. SWOT Analysis
  • 3.4.4. Recent Developments
• 3.5. Sanofi SA
  • 3.5.1. Overview
  • 3.5.2. Financial Analysis
  • 3.5.3. SWOT Analysis
  • 3.5.4. Recent Developments
• 3.6. Key Strategy Analysis

4. Market Segmentation

• 4.1. Global Hemoglobinopathies Market by Type
  • 4.1.1. Thalassemia
  • 4.1.2. Sickle Cell Disease
  • 4.1.3. Others (Hemoglobin (Hb) Variants)
• 4.2. Global Hemoglobinopathies Market by Therapy
  • 4.2.1. Monoclonal Antibody Medication
  • 4.2.2. ACE inhibitors
  • 4.2.3. Hydroxyurea
  • 4.2.4. Others (Blood Transfusion, Iron Chelation Therapy, and Bone Marrow Transplant)
• 4.3. Global Hemoglobinopathies Market by Distribution Channel
  • 4.3.1. Hospital Pharmacy
  • 4.3.2. Online Providers
  • 4.3.3. Drug Stores and Retail Pharmacy

5. Regional Analysis

• 5.1. North America
  • 5.1.1. United States
  • 5.1.2. Canada
• 5.2. Europe
  • 5.2.1. UK
  • 5.2.2. Germany
  • 5.2.3. Italy
  • 5.2.4. Spain
  • 5.2.5. France
  • 5.2.6. Rest of Europe
• 5.3. Asia-Pacific
  • 5.3.1. China
  • 5.3.2. India
  • 5.3.3. Japan
  • 5.3.4. South Korea
  • 5.3.5. Rest of Asia-Pacific
• 5.4. Rest of the World
  • 5.4.1. Latin America
  • 5.4.2. Middle East & Africa

6. Company Profiles

• 6.1. Abbott Laboratories
• 6.2. Alnylam Pharmaceuticals, Inc.
• 6.3. BIOGEN Inc.
• 6.4. Bio-Rad Laboratories Inc.
• 6.5. Bioverativ Inc.
• 6.6. Bluebird Bio Inc.
• 6.7. Canthera Discovery Ltd.
• 6.8. Celgene Corporation
• 6.9. Danaher Corporation
• 6.10. Emmaus Medical, Inc.
• 6.11. Gamida Cell Ltd.
• 6.12. Global Blood Therapeutics, Inc.
• 6.13. Merck & Co. Inc.
• 6.14. Mindray Medical International Ltd.
• 6.15. Nihon Kohden Corporation
• 6.16. PerkinElmer, Inc.
• 6.17. Prolong Pharmaceuticals LLC
• 6.18. Silence Therapeutics